-
Hyderabad: Hyderabad-based Granules India, a vertically integrated pharmaceutical company, appointed Dr Saumen Chakraborty as non-executive independent director on the Board of the company with immediate effect. Dr Chakraborty retired as the president and chief financial officer of Dr Reddy’s in November 2020 and continued to advise the company for the next one year. Commenting on […]
-
Hyderabad: Hyderabad-based Dr Reddy’s Laboratories and Prestige BioPharma have entered into a binding agreement for an exclusive partnership for the supply and commercialisation of Prestige BioPharma’s proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia. Prestige BioPharma’s trastuzumab (HD201) is a proposed biosimilar to Roche’s Herceptin and can be prescribed for the […]
-
Hyderabad: What could large enterprises like Adani Wilmar, Swiggy and JSW have in common? They all use the same HR technology platform that has been developed by three Hyderabad-based entrepreneurs. Darwinbox, which is a city-based HR technology startup have served over 600-plus clients since 2016 and has over 10 lakh users on its platform. The […]
-
Hyderabad: Hyderabad-based Dr Reddy’s Laboratories reported a consolidated profit after tax (PAT) of Rs 992 crore for the quarter, up 30 per cent from Rs 762 crore reported in the corresponding quarter last year. The company’s revenues saw a 18 per cent jump at Rs 5,763 crore for the quarter, as against Rs 4,897 crore […]
-
Hyderabad: Dr Reddy’s Laboratories created ‘Fastminar’, the world’s largest toothbrush sculpture of a body part dedicated to raising awareness of dentin hypersensitivity. Fastminar is a 40-feet structure made with approximately 80,000 toothbrushes and is located at Terna Dental College in Navi Mumbai. The monument has been certified by Guinness World Records as the largest toothbrush […]
-
Under the terms of agreement, Dr Reddy’s will receive $40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $40 million related to the CTCL (cutaneous T-cell lymphoma)
-
Reddy-Lenalidomide capsules are available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths, each in blister packs.
-
Under the terms of agreement, Dr Reddy’s will receive $6 million (about Rs 45 crore) upfront upon closing, followed by $9 million (over Rs 65 crore) one year from closing.
-
Hyderabad firm expects that the availability of imported vaccine doses will ease from August onwards to accelerate vaccination
-
Multi-service mobile app platform brings together doctors, laboratories & diagnostics, pharmacies, and insurance for a one-stop cashless and seamless outpatient user experience
-
The company's revenues increased by 11.4 per cent year-on-year to Rs 4,919.4 crore in Q1FY22 from Rs 4,728.4 crore in Q1FY21.
-
Demand for Covid pandemic-related drugs will continue to drive the growth momentum this fiscal
-
Soft launch of Sputnik V vaccine reaches over 50 cities and towns, after initial launch in Hyderabad on May 14
-
On successful completion of the clinical trial, each company will independently approach the regulatory authorities for approval to manufacture and supply the drug for the treatment of Covid-19 in India
-
With the Maximum Retail Price (MRP) of each sachet fixed at Rs 990, the drug will be supplied to major governments as well as private hospitals across the country, said an official release.
-
Being a limited pilot phase presently, registration on CoWIN is not open yet to public, but will become open at the time of commercial launch.
-
In addition to storage, Rockwell will provide end-to-end logistics and after sales service support for the vaccine freezers across India
-
The Hyderabad-based drug major is voluntarily recalling the affected lots of the drug in 10 mg strength due to “failed impurities degradation specifications”.
-
The drug maker's growth would be primarily driven by organic moves, focusing around pipeline monetisation, productivity enhancement, diversifications.
-
The drug can be added as a supplement or adjunct to the existing treatment protocols to treat moderate to severe Covid patients
